PTCT
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- PTC Therapeutics completes acquisition of ST-920 Fabry disease gene therapySep 22, 2026
- PTC Therapeutics reported new Sephience data reinforcing broad patient benefits, including sustained metabolic control, greater dietary flexibility, and a consistent favorable safety profileAug 24, 2026
- PTC announced plans to expand its rare disease portfolio through the acquisition of the BLA-stage ST-920 Fabry disease programAug 13, 2026
- PTC Therapeutics reported positive topline results from the 24-month interim analysis of the PIVOT-HD extension study of VotoplamApr 29, 2026
- PTC Therapeutics announces approval of Sephience™ (sepiapterin) for PKU treatment in JapanDec 22, 2025